NIH Summit Seeks to Transform Alzheimer’s Research

NIH Summit Seeks to Transform Alzheimer’s Research
A recent meeting convened by the National Institutes of Health (NIH) could dramatically alter how researchers study Alzheimer's disease (AD).  The NIH issued new recommendations, based on the recent Alzheimer's Disease Research Summit, which could speed up work leading to the development of treatments for AD. During the summit, more than 60 AD experts met to discuss research recommendations. “Alzheimer’s research is entering a new era in which creative approaches for detecting, measuring and analyzing a wide range of biomedical data sets are leading to new insights about the causes and course of the disease,” stated NIH Director Francis S. Collins, M.D., Ph.D. “In these times of significant fiscal constraints, we need to work smarter, faster and more collaboratively. These recommendations underscore the importance of data sharing and multidisciplinary partnerships to a research community that looks to the NIH for guidance on the way forward.” The recommendations may help academia, government and industry to work together more effectively. “Determining the best path for progress in Alzheimer’s disease research has been as challenging and complicated as the disorder itself,” remarked National Institute of Aging (NIA) Director Richard J. Hodes, M.D. “These recommendations support a research framework that empowers all stakeholders — including those with the disease or at risk for developing it — to engage in the vital effort to find treatments.” The meeting occurred on February 9-10, 2015, and included 500 participants onsite, and 500 additional participants via videocast. General suggestions developed
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *